Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. (Nasdaq: ENSC) is a clinical-stage pharmaceutical company focused on developing abuse-deterrent opioid and stimulant treatments using its proprietary TAAP and MPAR drug-delivery technologies. The company filed an amended annual report (Form 10-K/A) with the SEC on March 12, 2019, accession number 0001615774-19-003970, covering activity ahead of its eventual de-SPAC transaction. Ensysce completed its merger with LifeSci Acquisition Corp, sponsored by LifeSci Capital LLC, in 2021, uplisting to Nasdaq under the ENSC ticker through that healthcare-sector SPAC. The company operates in the biopharmaceuticals industry with a clinical pipeline targeting prescription opioid abuse prevention. Sign up at SpacDesk for full filing history, sponsor data, and real-time deal analytics on ENSC and hundreds of other SPAC transactions.